Michael Vishnevetsky

Biography
Michael Vishnevetsky is a seasoned commercial leader with extensive experience scaling companies in the genomics, diagnostics, and precision oncology space. Throughout his career, Michael has built high-impact strategic alliances and led commercial teams at industry-leading companies including Fabric Genomics, Personal Genome Diagnostics, and Invivoscribe. He brings a deep expertise in biopharma partnerships and companion diagnostics strategy, helping to connect innovative technologies with clinical and pharmaceutical partners.

---

Talk
Streamlining Precision Oncology: Flexible Pipelines for CGPLiquid Biopsy
This session introduces a next-generation, end-to-end bioinformatics solution for today's CGP and liquid biopsy labs. We demonstrate how this unified platform streamlines the entire analytical workflow, from raw FASTQ data to comprehensive report. We'll highlight the software's flexible architecture, which empowers labs to adapt to diverse assays, scale operations, and accelerate precision oncology.

AI for Clinical Decision Support Systems Showcase:
SeqOne
SeqOne is a leading European provider of AI-powered software for NGS data analysis in oncology and rare diseases. The cloud platform is HIPAA compliant and CE-IVD Class C certified. It transforms complex genomic data into fast, actionable insights, supporting molecular labs in delivering life-saving personalized treatments and scaling genomic medicine for every patient, everywhere.

Rachel Gollub

Biography
Rachel Gollub is a serial entrepreneur and inventor, currently focused on precision medicine.Her goal is to bring rigor and precision to the prescription process. A Caltech graduate, she was on the team that wrote the Java language, then worked at Silicon Valley startups until she began to found her own.Her previous startup was acquired by UnitedHealth Group, where she worked as CTO of the EI space for several years before founding PointHealth AI.

---

Talk
AI in Treatment Decision Support
PointHealth AI is the leader in AI treatment decision support. We use reinforcement learning on millions of similar patients to determine the most effective prescriptions for a given condition. We provide a full report, integrated with the major EHR systems, in realtime at the point of diagnosis. Come learn how!

AI for Clinical Decision Support Systems Showcase:
PointHealth AI
PointHealth AI was founded in 2024 in concert with the super{set} startup incubator, and brings precision medicine to clinicians across the world.

Travis Zack

Biography
Dr. Travis Zack is Chief Physician at OpenEvidence and an adjunct professor at UCSF with a lab in predictive model development in real-world health data. His research lies at the intersection of computational biology, clinical medicine, and artificial intelligence. Travis received his PhD in Biophysics from Harvard and an MD in the Health Sciences and Technology track at MIT and Harvard Medical School. Dr. Zack has dedicated his career to using data-driven approaches to address pressing challenges in oncology. His lab focuses on developing AI models to support clinical decision-making and enhance patient outcomes, including machine learningbased tools for real-world evidence studies and natural language processing methods to extract valuable insights from electronic health records.

---

Talk
Award presentation
Award presentation

AI for Clinical Decision Support Systems Showcase:
OpenEvidence
Medical search platform

Cathy Shyr

Biography
Cathy Shyr is an assistant professor of biomedical informatics, pediatrics, and biostatistics at Vanderbilt University Medical Center. She received her PhD in biostatistics from Harvard University and is a statistical informatician specializing in machine learning (ML), AI, and causal inference methods for estimating personalized treatment effects. Her research focuses on the development and implementation of novel statistical ML and AI methods to advance precision medicine. Dr. Shyr leads the AI initiatives at the Vanderbilt Undiagnosed Diseases Network, developing and implementing large language models that leverage electronic health records data to accelerate rare disease diagnosis. She has developed methods that improve the generalizability of statistical ML and causal inference models across multiple heterogeneous datasets for estimating personalized risks and treatment effects. She is an active member of the All of Us Research Programs Data and Research Center, where she leads the development of AI tools supporting the return of study results.

---

Talk
Accelerating Rare Disease Diagnosis with Artificial Intelligence
This showcase highlights AI and statistical machine learning methods developed using real-world rare disease patient data at the Vanderbilt Undiagnosed Diseases Network to improve diagnostic accuracy and efficiency. These tools provide a scalable, reproducible framework for accelerating diagnoses for health systems evaluating undiagnosed patients with complex and rare conditions.

AI for Clinical Decision Support Systems Showcase:
Vanderbilt University Medical Center
Vanderbilt University Medical Center (VUMC) is a leading academic medical center and research institution known for its nationally recognized clinical programs, biomedical innovation, and translational science. VUMC integrates patient care, research, and education to advance precision medicine and improve health outcomes.

Luca Emili

Biography
Luca is a seasoned entrepreneur and expert in technology and healthcare, with a longstanding focus on advancing modeling and simulation within the life sciences sector. Prior to his current endeavors, he was the CEO of Emaze, a cybersecurity firm that specialized in automated security analysis for complex networks. He is actively involved in several advisory roles, including the Cloud Security Consultative Group at EMA, Co-chair of Avicenna Alliance's Good Simulation Practice (GSP) Task Force and member of the committee for the adoption of In Silico Medicine of the Italian Ministry of Health. He is also co-editor of the open-access book "Toward Good Simulation Practice: Best Practices for the Use of Computational ModelingSimulation in the Regulatory Process of Biomedical Products, published open access by Nature Springer in February 2024.

---

Talk
Transforming Clinical Trial Simulation with Causal GenAI
We explore how InSilicoTrials leverages Causal GenAI and advanced Digital Twin technologies to transform clinical trial simulation. Discover how AI-driven modeling accelerates study design, reduces risk, and enhances decision-making, enabling faster, smarter, and more efficient drug development.

AI for Clinical Decision Support Systems Showcase:
InSilicoTrials
We provide a cloud-based platform that uses in silico modeling, predictive AI, and synthetic patient simulations to generate robust, regulatory-grade digital evidence; accelerating the go-to-market timeline and extending market exclusivity up to 4 years.

Abraham Lin

Biography
Abraham Lin is the cofounder and CEO of Orbits Oncology, an academic spinout focused on transforming a patients own tumor tissue into actionable insights to personalize cancer treatment. He has harmonized advanced tumor models, live-microscopy imaging, and AI-driven analysis to predict how individual tumors respond to therapy. Trained as an engineer before transitioning into cancer research, Abraham has authored more than 45 scientific publications, holds 4 patents, and received multiple international research awards. His goal has always been to bring more engineering solutions into oncology to benefit researchers and cancer patients. After years of developing academic innovations at the intersection of engineering and oncology, he was compelled to pursue entrepreneurship to translate these advances into real-world solutions and large societal impacts. Today, he applies his extensive cross-disciplinary experience in leading Orbits Oncologys efforts to build scalable, predictive tools that improve cancer care for patients and development of novel therapies.

---

Talk
Unlocking patient organoids for personalized cancer medicine
Patient-derived organoids are a major breakthrough in 3D tumor lab cultures, but their predictive value remains largely untapped. This talk explores how our AI-powered analysis platform transforms organoids into predictive tools of real-world patient therapy response, unlocking new possibilities for developing novel therapies and personalizing cancer patient care.

AI for Clinical Decision Support Systems Showcase:
Orbits Oncology
Orbits Oncology provides a personalized medicine test that predicts which cancer therapies are most likely to work for each patient, before treatment begins. Using a sample of the patient’s own tumor, we grow lab-tumor models, expose them to medicines from a list of approved options, and identify the most promising therapies for that specific patient.

Mann Parikh

Biography
Mann Parikh leads NerView Surgical, a medtech startup developing NerveSense, a contact-free imaging platform that makes peripheral nerves visible in real time during surgery. His work focuses on translating physics-based optics and AI into practical tools that reduce iatrogenic nerve injury across plastic, endocrine, and head and neck surgery.He has guided the company through multiple prototype generations, GLP-aligned preclinical study design, and early FDA engagement, securing competitive non-dilutive funding and building partnerships with leading centers such as Stanford, Mayo Clinic, and Harvard-affiliated hospitals. Beyond NerView, he contributes to surgical innovation and global health initiatives as a mentor, educator, and advisor to students and early-stage founders.

---

Talk
Real-Time Optical Mapping of Surgical Nerves
NerView Surgicals NerveSense platform uses polarized light, computer vision, and AI to give surgeons a real-time, contact-free map of peripheral nerves during open surgery. I will share preclinical and early clinical data, show how we align optical physics with surgical workflow, and outline our evidence and regulatory roadmap.

AI for Clinical Decision Support Systems Showcase:
NerView Surgical Inc.
NerView Surgical develops NerveSense, a handheld, contact-free imaging system that uses polarized light and AI to make peripheral nerves visible in real time during surgery. By standardizing intraoperative nerve visualization, we aim to reduce iatrogenic nerve injury and its clinical, economic, and medico-legal burden.

Glenn Loomis

Biography
A published leader in healthcare technology and medical AICurrently the Founder and CEO of Query Health5 years as a startup leader - Medical Group President for 30 Madison20+ years health system leader - CMO and Medical Group President for mid sized health systems10 years as a Family Medicine educator - Faculty and Residency DirectorUS Air Force VeteranBoard Certified in Family MedicineAI Medicine.Multiple roles in medical societies, including AMA, AAFP, AMGA and state chaptersWrote the AMA primer on AI in Medicine.

---

Talk
Beyond Scribes: An AI Doctor Assistant
Discussion of how AI can help doctors scale, by completing the data extraction portion of every visit and turning those patient conversations into actionable data, diagnostic recommendations and proposed treatment plans.

AI for Clinical Decision Support Systems Showcase:
Query Health
Query Health is a native GenAI platform revolutionizing the provider-patient relationship by automating patient intake, providing clinical decision support to physicians, and offering secure, data-driven patient insights.We save physicians’ time, create a better patient experience, and offer a 5X ROI for practices.

Alexander Lai

Biography
Alexander G. Lai currently spearheads the development and strategic direction of VincoAI, a pioneering generative AI platform designed to predict peptide-protein binding sequences. His work focuses on transforming drug discovery by integrating high-fidelity in silico modeling to identify therapeutic candidates for complex challenges, including antimicrobial resistance (AMR) and viral proteases.He is a recognized innovator in the biotechnology sector, having been named to the INNO Under 25 list for his contributions to AI-driven precision medicine. His professional history includes delivering key technical presentations at prestigious global forums such as the BIO CEOInvestor Conference and the World AMR Congress.He holds a Bachelors degree in Biology from Penn State University and a Masters degree in Biotechnology from Harvard University. His academic and professional career has been defined by bridging the gap between computational biology and translational medicine to accelerate the delivery of safe, targeted therapeutics.

---

Talk
In-Silico Drug Discovery, Human-Predictive
Talk Synopsis:In-Silico Drug Discovery, Human-Predictive presents VincoAIs platform, which models physiological protein interactions, reconstructs human signaling pathways, and enables multi-scale in-silico testing of biologics. The talk highlights how this approach reduces preclinical risk, accelerates target validation, and transforms drug discovery months before wet-lab experiments.

AI for Clinical Decision Support Systems Showcase:
Vincogen corporation
Vincogen is a AI biotechnology company developing human-predictive biologics using its proprietary VincoAI platform, which models physiological protein–protein interactions, reconstructs disease signaling pathways, and enables multi-scale in-silico drug discovery across viral, immune, and complex human diseases.

Phillippe Spiess

Biography
An internationally recognized urologic oncologist, academic surgeon, and healthcare innovator specializing in complex and rare genitourinary malignancies. A senior faculty at Moffitt Cancer Center, where he serves as Medical Director of Virtual Care advancing innovation focused care delivery, multidisciplinary oncology models, and second-opinion services. Dr. Spiess completed advanced surgical and oncologic training at McGill University and University of Texas MD Anderson Cancer Center, respectively and holds formal certification in Artificial Intelligence from Oxford University, with ongoing advanced AI leadership training.He has authored over 520 peer-reviewed publications with an H-index exceeding 50, and has received multiple academic and teaching awards including being the 2025 Moffitt Physician of the Year. Dr. Spiess holds prominent national and international leadership roles for the NCCN, ASCO, AUA, EAU, and ESMO. He also serves as Chief Medical Officer of OncoBrain AI, where he helps lead clinical strategy for AI-driven oncology education and decision-support platforms.

---

Talk
From Hours to Minutes: Rethinking Clinical Support in Oncology
Oncobrain helps oncologists move through complex decisions with clarity. It consumes and interprets data like an expert and grounds every recommendation in NCCNASCO guidelines with transparent reasoning, citations, and accuracy scoring. Designed to reduce cognitive load, it supports clinical judgment, surfaces helpful questions, offers optional specialist review, and strengthens confidence in decisions.

AI for Clinical Decision Support Systems Showcase:
Oncobrain
Oncobrain is an oncology-specific clinical reasoning engine that delivers optimal, guideline-concordant, patient-specific insights and treatment plans at the point of care. Built on data from over 1M patients, 2400 data points per oncology case and coupled with NCCN and ASCO guidelines, it turns complex data into clear, actionable recommendations that reduce variation, support clinicians, and improve treatment planning and quality.

Phillippe Spiess

Biography
An internationally recognized urologic oncologist, academic surgeon, and healthcare innovator specializing in complex and rare genitourinary malignancies. A senior faculty at Moffitt Cancer Center, where he serves as Medical Director of Virtual Care advancing innovation focused care delivery, multidisciplinary oncology models, and second-opinion services. Dr. Spiess completed advanced surgical and oncologic training at McGill University and University of Texas MD Anderson Cancer Center, respectively and holds formal certification in Artificial Intelligence from Oxford University, with ongoing advanced AI leadership training.He has authored over 520 peer-reviewed publications with an H-index exceeding 50, and has received multiple academic and teaching awards including being the 2025 Moffitt Physician of the Year. Dr. Spiess holds prominent national and international leadership roles for the NCCN, ASCO, AUA, EAU, and ESMO. He also serves as Chief Medical Officer of OncoBrain AI, where he helps lead clinical strategy for AI-driven oncology education and decision-support platforms.

AI for Clinical Decision Support Systems Showcase:
Oncobrain
Oncobrain is an oncology-specific clinical reasoning engine that delivers optimal, guideline-concordant, patient-specific insights and treatment plans at the point of care. Built on data from over 1M patients, 2400 data points per oncology case and coupled with NCCN and ASCO guidelines, it turns complex data into clear, actionable recommendations that reduce variation, support clinicians, and improve treatment planning and quality.